Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists

GABA_A Receptor Channels

Macdonald, R. L., & Olsen, R. W. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.003033 · Cited by 1,975 · see citing works

GABA regulates synaptic integration of newly generated neurons in the adult brain

Ge, S., Goh, E. L. K., Sailor, K. A., Kitabatake, Y., Ming, G., & Song, H. (2005) · Nature · doi:10.1038/nature04404 · Cited by 1,261 · see citing works

GABA _A ‐receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits

Fritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244 · see citing works

The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development

Laurie, D., Wisden, W., & Seeburg, P. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04151.1992 · Cited by 1,144 · see citing works

GABAA receptors: Subtypes provide diversity of function and pharmacology

Olsen, R. W., & Sieghart, W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.045 · Cited by 986 · see citing works

A mouse model for Down syndrome exhibits learning and behaviour deficits

Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · see citing works

GABAergic Excitation Promotes Neuronal Differentiation in Adult Hippocampal Progenitor Cells

Tozuka, Y., Fukuda, S., Namba, T., Seki, T., & Hisatsune, T. (2005) · Neuron · doi:10.1016/j.neuron.2005.08.023 · Cited by 741 · see citing works

Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes

Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · see citing works

Enhanced Learning and Memory and Altered GABAergic Synaptic Transmission in Mice Lacking the α5 Subunit of the GABA _A Receptor

Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · see citing works

SEVERE ANXIETY INDUCED BY FG 7142, A β-CARBOLINE LIGAND FOR BENZODIAZEPINE RECEPTORS

Dorow, R., Horowski, R., Paschelke, G., Amin, M., & Bræstrup, C. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90076-4 · Cited by 580 · see citing works

Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors

Caraiscos, V. B., Elliott, E. M., You-Ten, K. E., Cheng, V., Belelli, D., Newell, J. G., Jackson, M. F., Lambert, J. J., Rosahl, T. W., Wafford, K. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307231101 · Cited by 571 · see citing works

Epidemiology of Down syndrome

Sherman, S. L., Allen, E. G., Bean, L., & Freeman, S. B. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20157 · Cited by 531 · see citing works

Trace fear conditioning involves hippocampal α ₅ GABA _A receptors

Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blüthmann, H., Möhler, H., & Rudolph, U. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142288699 · Cited by 528 · see citing works

Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R. C., & Garner, C. C. (2007) · Nature Neuroscience · doi:10.1038/nn1860 · Cited by 509 · see citing works

The four ages of Down syndrome.

Bittles, A., Bower, C., Hussain, R., & Glasson, E. (2007) · European Journal of Public Health · doi:10.1093/eurpub/ckl103 · Cited by 505 · see citing works

GABA-based therapeutic approaches: GABAA receptor subtype functions

RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · see citing works

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484 · see citing works

From ion currents to genomic analysis: Recent advances in GABAA receptor research

Rabow, L. E., Russek, S. J., & Farb, D. H. (1995) · Synapse · doi:10.1002/syn.890210302 · Cited by 469 · see citing works

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome

Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459 · see citing works

Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome

Holtzman, D. M., Santucci, D., Kilbridge, J., Chua-Couzens, J., Fontana, D. J., Daniels, S. E., Johnson, R. M., Chen, K., Sun, Y., Carlson, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13333 · Cited by 448 · see citing works

The amnesic action of benzodiazepines in man

Lister, R. G. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90034-x · Cited by 448 · see citing works

Activation of immediate early genes and memory formation

Tischmeyer, W., & Grimm, R. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050315 · Cited by 422 · see citing works

Mapping behaviorally relevant neural circuits with immediate-early gene expression

Guzowski, J. F., Timlin, J. A., Roysam, B., McNaughton, B. L., Worley, P. F., & Barnes, C. A. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.08.018 · Cited by 404 · see citing works

KCC2 Expression Promotes the Termination of Cortical Interneuron Migration in a Voltage-Sensitive Calcium-Dependent Manner

Bortone, D., & Polleux, F. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.034 · Cited by 387 · see citing works

Molecular and Functional Diversity of the Expanding GABA‐A Receptor Gene Family

Whiting, P. J., Bonnert, T. P., McKernan, R. M., Farrar, S. J., Bourdellès, B. L., HEAVENS, R. P., SMITH, D. W., Hewson, L., Rigby, M. R., SIRINATHSINGHJI, D. J. S., et al. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11341.x · Cited by 345 · see citing works

Benzodiazepines and Human Memory: A Review

Ghoneim, M. M., & Mewaldt, S. P. (1990) · Anesthesiology · doi:10.1097/00000542-199005000-00024 · Cited by 305 · see citing works

θ, a novel γ-aminobutyric acid type A receptor subunit

Bonnert, T. P., McKernan, R. M., Farrar, S. J., Bourdellès, B. L., HEAVENS, R. P., Smith, D. W., Hewson, L., Rigby, M. R., SIRINATHSINGHJI, D. J. S., Brown, N. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9891 · Cited by 303 · see citing works

Synaptic structural abnormalities in the Ts65Dn mouse model of down syndrome

Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297 · see citing works

DOG BITES IN CHILDREN

Lillington, A. W., & Ross, M. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92316-3 · Cited by 261 · see citing works

GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus

Klausberger, T. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06913.x · Cited by 260 · see citing works

Olig1 and Olig2 triplication causes developmental brain defects in down syndrome.

Chakrabarti, L., Best, T. K., Cramer, N. P., Carney, R. S. E., Isaac, J. T. R., Galdzicki, Z., & Haydar, T. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2600 · Cited by 258 · see citing works

An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition

Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241 · see citing works

A behavioral assessment of Ts65Dn mice: a putative Down syndrome model

Escorihuela, R. M., Fernández‐Teruel, A., Vallina, I. F., Baamonde, C., Lumbreras, M., Dierssen, M., Tobeña, A., & Flórez, J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12052-6 · Cited by 234 · see citing works

Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome

Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · see citing works

Hippocampal Network Hyperactivity After Selective Reduction of Tonic Inhibition in GABAA Receptor α5 Subunit–Deficient Mice

Glykys, J. C., & Módy, I. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01122.2005 · Cited by 216 · see citing works

GABAergic Control of Adult Hippocampal Neurogenesis in Relation to Behavior Indicative of Trait Anxiety and Depression States

Earnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., & Lüscher, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3609-06.2007 · Cited by 203 · see citing works

Trisomy 21 and early brain development

Haydar, T. F., & Reeves, R. H. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.001 · Cited by 200 · see citing works

Photoaffinity Labeling of Benzodiazepine Receptor Proteins with the Partial Inverse Agonist [3H]Ro 15–4513: A Biochemical and Autoradiographic Study

Sieghart, W., Eichinger, A., Richards, J. G., & Möhler, H. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb13125.x · Cited by 191 · see citing works

Down's syndrome: Is there a decreased population of neurons?

Ross, M. H., Galaburda, A. M., & Kemper, T. L. (1984) · Neurology · doi:10.1212/wnl.34.7.909 · Cited by 191 · see citing works

Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for down syndrome

Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., & Bartesaghi, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0534-10.2010 · Cited by 188 · see citing works

Down syndrome, Alzheimer’s disease and seizures

Menéndez, M. (2005) · Brain and Development · doi:10.1016/j.braindev.2004.07.008 · Cited by 186 · see citing works

Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome

Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., & Galdzicki, Z. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00083-0 · Cited by 184 · see citing works

[Mongolism; a chromosomal disease (trisomy)].

LEJEUNE, J., Turpin, R., & Gautier, M. (1959) · PubMed · Cited by 183 · see citing works

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors

Atack, J. R., Bayley, P. J., Seabrook, G. R., Wafford, K. A., McKernan, R. M., & Dawson, G. R. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.018 · Cited by 175 · see citing works

Deficits in Cognition and Synaptic Plasticity in a Mouse Model of Down Syndrome Ameliorated by GABAB Receptor Antagonists

Kleschevnikov, A. M., Belichenko, P. V., Faizi, M., Jacobs, L. F., Htun, K. E., Shamloo, M., & Mobley, W. C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1673-12.2012 · Cited by 174 · see citing works

Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of down syndrome.

Costa, A. C. S., & Grybko, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.031 · Cited by 174 · see citing works

Seizure Disorders in Down Syndrome

Pueschel, S. M., Louis, S., & McKnight, P. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530150088024 · Cited by 171 · see citing works

Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities

Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171 · see citing works

Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome

Martı́nez-Cué, C., Baamonde, C., Lumbreras, M., Paz, J., Davisson, M. T., Schmidt, C., Dierssen, M., & Flórez, J. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00026-8 · Cited by 166 · see citing works

Synaptic and nonsynaptic localization of GABAAreceptors containing the α5 subunit in the rat brain

Serwanski, D. R., Miralles, C. P., Christie, S. B., Mehta, A. K., Li, X., & Blas, A. L. D. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.21115 · Cited by 164 · see citing works

Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test

Costa, A. C. S., Scott-McKean, J. J., & Stasko, M. R. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301535 · Cited by 163 · see citing works

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice

Braudeau, J., Delatour, B., Duchon, A., Pereira, P. L., Dauphinot, L., de Chaumont, F., Olivo‐Marín, J., Dodd, R. H., Hérault, Y., & Potier, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111405366 · Cited by 163 · see citing works

Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome

Escorihuela, R. M., Vallina, I. F., Martínez‐Cué, C., Baamonde, C., Dierssen, M., Tobeña, A., Flórez, J., & Fernández‐Teruel, A. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00317-6 · Cited by 161 · see citing works

Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome

Salehi, A., Faizi, M., Colas, D., Valletta, J. S., Laguna, J., Takimoto‐Kimura, R., Kleschevnikov, A. M., Wagner, S. L., Aisen, P. S. S., Shamloo, M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000258 · Cited by 159 · see citing works

Lithium rescues synaptic plasticity and memory in Down syndrome mice

Contestabile, A., Greco, B., Ghezzi, D., Tucci, V., Benfenati, F., & Gasparini, L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64650 · Cited by 157 · see citing works

RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors

Ballard, T. M., Knoflach, F., Prinssen, E. P. M., Borroni, E., Vivian, J. A., Basile, J., Gasser, R., Moreau, J., Wettstein, J. G., Buettelmann, B., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1357-7 · Cited by 156 · see citing works

Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome

Martínez‐Cué, C., Martinez, P. M., Rueda, N., Vidal, R., García-Cerro, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1203-12.2013 · Cited by 154 · see citing works

Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of down syndrome.

Insausti, A. M., Megı́as, M., Crespo, D., Cruz-Orive, L. M., Dierssen, M., Vallina, T. F., Insausti, R., & Flórez, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00641-7 · Cited by 149 · see citing works

Global disruption of the cerebellar transcriptome in a Down syndrome mouse model

Saran, N. G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg217 · Cited by 143 · see citing works

Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome

Clark, S. M., Schwalbe, J., Stasko, M. R., Yarowsky, P., & Costa, A. C. S. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.02.005 · Cited by 142 · see citing works

Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome.

Belichenko, P. V., Kleschevnikov, A. M., Masliah, E., Wu, C., Takimoto‐Kimura, R., Salehi, A., & Mobley, W. C. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21895 · Cited by 141 · see citing works

Behavioral assessment of the Ts65Dn mouse, a model for down syndrome: Altered behavior in the elevated plus maze and open field

Coussons‐Read, M. E., & Crnic, L. S. (1996) · Behavior Genetics · doi:10.1007/bf02361154 · Cited by 139 · see citing works

Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling

Little, H. J., Nutt, D., & Taylor, S. C. (1984) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1984.tb16536.x · Cited by 135 · see citing works

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer

Faizi, M., Bader, P. L., Tun, C., Encarnacion, A., Kleschevnikov, A. M., Belichenko, P. V., Saw, N. L., Priestley, M., Tsien, R. W., Mobley, W. C., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.011 · Cited by 134 · see citing works

Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model

Das, I., Park, J. M., Shin, J. H., Jeon, S. K., Lorenzi, H., Linden, D. J., Worley, P. F., & Reeves, R. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005983 · Cited by 134 · see citing works

GABAA receptors containing the α5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear

Yee, B. K., Hauser, J., Dolgov, V. V., Keist, R., Möhler, H., Rudolph, U., & Feldon, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03642.x · Cited by 132 · see citing works

Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome

Rueda, N., Flórez, J., & Martínez‐Cué, C. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.039 · Cited by 127 · see citing works

Fetal Down Syndrome Brains Exhibit Aberrant Levels of Neurotransmitters Critical for Normal Brain Development

Whittle, N., Sartori, S. B., Dierssen, M., Lubec, G., & Singewald, N. (2007) · Pediatrics · doi:10.1542/peds.2006-3448 · Cited by 127 · see citing works

Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome

Ayberk Kurt, M., Ilker Kafa, M., Dierssen, M., & Ceri Davies, D. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.075 · Cited by 126 · see citing works

Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome

Kleschevnikov, A. M., Belichenko, P. V., Gall, J., George, L., Nosheny, R., Maloney, M. T., Salehi, A., & Mobley, W. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.009 · Cited by 124 · see citing works

α5GABAA Receptors Regulate the Intrinsic Excitability of Mouse Hippocampal Pyramidal Neurons

Bonin, R. P., Martin, L. J., MacDonald, J. F., & Orser, B. A. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00482.2007 · Cited by 118 · see citing works

Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions

Sturgeon, X., & Gardiner, K. J. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9321-y · Cited by 117 · see citing works

Ts65Dn, a Mouse Model of Down Syndrome, Exhibits Increased GABAB-Induced Potassium Current

Best, T. K., Siarey, R. J., & Galdzicki, Z. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00626.2006 · Cited by 117 · see citing works

Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA

Atack, J. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.001 · Cited by 116 · see citing works

Imaging the GABA-Benzodiazepine Receptor Subtype Containing the α5-Subunit In Vivo with [ 11 C]Ro15 4513 Positron Emission Tomography

Lingford-Hughes, A. R., Hume, S. P., Feeney, A., Hirani, E., Osman, S., Cunningham, V. J., Pike, V. W., Brooks, D. J., & Nutt, D. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200207000-00013 · Cited by 112 · see citing works

Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology

Seidl, R., Cairns, N. J., Singewald, N., Kaehler, S. T., & Lübec, G. (2001) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100000346 · Cited by 109 · see citing works

An Orally Bioavailable, Functionally Selective Inverse Agonist at the Benzodiazepine Site of GABAA α5 Receptors with Cognition Enhancing Properties

Chambers, M. S., Atack, J. R., Carling, R. W., Collinson, N., Cook, S. M., Dawson, G. R., Ferris, P., Hobbs, S. C., O'Connor, D. V., Marshall, G. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040863t · Cited by 109 · see citing works

Blockade of alcohol's amnestic activity in humans by an α5 subtype benzodiazepine receptor inverse agonist

Nutt, D., Besson, M. J., Wilson, S. J., Dawson, G. R., & Lingford-Hughes, A. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.008 · Cited by 109 · see citing works

Benzodiazepines block long-term potentiation in slices of hippocampus and piriform cortex

del Cerro, S., Jung, M., & Lynch, G. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90071-9 · Cited by 106 · see citing works

Selective, Orally Active γ-Aminobutyric Acid A α5 Receptor Inverse Agonists as Cognition Enhancers

Sternfeld, F., Carling, R. W., Jelley, R. A., Ladduwahetty, T., Merchant, K. J., Moore, K. W., Reeve, A. J., Street, L. J., O'Connor, D. V., Sohal, B., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031076j · Cited by 104 · see citing works

An inverse agonist selective for α5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze

Collinson, N., Atack, J. R., Laughton, P., Dawson, G. R., & Stephens, D. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0361-z · Cited by 96 · see citing works

The GABAA receptors. From subunits to diverse functions.

Möhler, H., Fritschy, J., Lüscher, B., Rudolph, U., Benson, J. A., & Benke, D. (1996) · PubMed · Cited by 95 · see citing works

The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome

Hanson, J. E., Blank, M., Valenzuela, R. A., Garner, C. C., & Madison, D. V. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.114868 · Cited by 94 · see citing works

Effects of benzodiazepines on acquisition and performance: A critical assessment

Cole, S. O. (1986) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(86)90013-8 · Cited by 87 · see citing works

The GABAA Receptors

Möhler, H., Fritschy, J., Lüscher, B., Rudolph, U., Benson, J. A., & Benke, D. (1996) · Springer eBooks · doi:10.1007/978-1-4899-1775-1_3 · Cited by 86 · see citing works

Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for down’s syndrome.

Pérez-Cremades, D., Hernández, S., Blasco-Ibáñez, J. M., Crespo, C., Nacher, J., & Varea, E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0376-9 · Cited by 85 · see citing works

Effects of pentylenetetrazol on memory storage in mice

Krivanek, J. A., & McGaugh, J. L. (1968) · Psychopharmacology · doi:10.1007/bf00401409 · Cited by 83 · see citing works

Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome

Begenisic, T., Spolidoro, M., Braschi, C., Baroncelli, L., Milanese, M., Pietra, G., Fabbri, M. E., Bonanno, G., Cioni, G., Maffei, L., et al. (2011) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2011.00029 · Cited by 82 · see citing works

Lithium Restores Neurogenesis in the Subventricular Zone of the Ts65Dn Mouse, a Model for Down Syndrome

Bianchi, P., Ciani, E., Contestabile, A., Guidi, S., & Bartesaghi, R. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00246.x · Cited by 80 · see citing works

A Critical Period in Cortical Interneuron Neurogenesis in Down Syndrome Revealed by Human Neural Progenitor Cells

Bhattacharyya, A., McMillan, E., Chen, S. I., Wallace, K., & Svendsen, C. N. (2009) · Developmental Neuroscience · doi:10.1159/000236899 · Cited by 79 · see citing works

THE PREVALENCE OF EPILEPSY AMONG MONGOLS RELATED TO AGE

Veall, R. M. (1974) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.1974.tb01224.x · Cited by 76 · see citing works

Modulation of Long-term Potentiation in CA1 Region of Mouse Hippocampal Brain Slices by GABAA Receptor Benzodiazepine Site Ligands

Seabrook, G. R., Easter, A., Dawson, G. R., & Bowery, B. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00040-3 · Cited by 75 · see citing works

Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of down syndrome

Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75 · see citing works

Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome

Best, T. K., Cramer, N., Chakrabarti, L., Haydar, T. F., & Galdzicki, Z. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.033 · Cited by 74 · see citing works

Is it possible to improve neurodevelopmental abnormalities in Down syndrome?

Bartesaghi, R., Guidi, S., & Ciani, E. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.037 · Cited by 74 · see citing works

Long‐term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle‐aged T s65 D n mice, a model of D own syndrome

Corrales, A., Martinez, P. M., García-Cerro, S., Vidal, V., García, E., Flórez, J., Sánchez‐Barceló, E. J., Martínez‐Cué, C., & Rueda, N. (2012) · Journal of Pineal Research · doi:10.1111/jpi.12037 · Cited by 69 · see citing works

Short‐term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro‐cognitive benefit in a mouse model of D own's syndrome

Colas, D., Chuluun, B., Warrier, D. R., Blank, M., Wetmore, D. Z., Buckmaster, P. S., Garner, C. C., & Heller, H. C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12169 · Cited by 63 · see citing works

Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome

Rueda, N., Mostany, R., Pazos, Á., Flórez, J., & Martínez‐Cué, C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.01.039 · Cited by 61 · see citing works

Differential pharmacological effects of benzodiazepine receptor inverse agonists.

Petersen, E. N., Lh, J., Honoré, T., & Bræstrup, C. (1983) · PubMed · Cited by 61 · see citing works

Socio-cognitive understanding: a strength or weakness in Down's syndrome?

Wishart, J. G. (2007) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2007.01007.x · Cited by 60 · see citing works

From the Behavioral Pharmacology of Beta-Carbolines to Seizures, Anxiety, and Memory

Venault, P., & Chapouthier, G. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.48 · Cited by 56 · see citing works

Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue

Reynolds, G. P., & Warner, C. E. J. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90299-6 · Cited by 56 · see citing works

PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats

Savić, M. M., Clayton, T., Furtmüller, R., Gavrilović, I., Samardžić, J., Savic, S. D., Huck, S., Sieghart, W., & Cook, J. M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.020 · Cited by 54 · see citing works

Chronic Treatment with a Promnesiant GABA-A -Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model

Braudeau, J., Dauphinot, L., Duchon, A., Loistron, A., Dodd, R. H., Hérault, Y., Delatour, B., & Potier, M. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/153218 · Cited by 53 · see citing works

Differential effects of benzodiazepine receptor agonists on hippocampal long-term potentiation and spatial learning in the Morris water maze

McNamara, R. K., dePape, G. E., & Skelton, R. W. (1993) · Brain Research · doi:10.1016/0006-8993(93)90563-3 · Cited by 52 · see citing works

Impaired Sustained Attention and Error-Induced Stereotypy in the Aged Ts65Dn Mouse: A Mouse Model of Down Syndrome and Alzheimer's Disease.

Driscoll, L. L., Carroll, J. C., Moon, J., Crnic, L. S., Levitsky, D. A., & Strupp, B. J. (2004) · Behavioral Neuroscience · doi:10.1037/0735-7044.118.6.1196 · Cited by 51 · see citing works

Psychotogenic properties of benzodiazepine receptor inverse agonists

Sarter, M. F., Bruno, J. P., & Berntson, G. G. (2001) · Psychopharmacology · doi:10.1007/s002130100756 · Cited by 48 · see citing works

Sleep and EEG features in genetic models of Down syndrome

Colas, D., Valletta, J. S., Takimoto‐Kimura, R., Nishino, S., Fujiki, N., Mobley, W. C., & Mignot, E. J.-M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.014 · Cited by 45 · see citing works

DURING NALTREXONE-PRECIPITATED OPIATE WITHDRAWAL

Duka, T., & ATTFIELD, S. (1996) · Behavioural Pharmacology · doi:10.1097/00008877-199605001-00072 · Cited by 40 · see citing works

Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment

Huang, W., Galdzicki, Z., van Gelderen, P., Balbo, A., Chikhale, E. G., Schapiro, M. B., & Rapoport, S. I. (2000) · Neuroreport · doi:10.1097/00001756-200002280-00004 · Cited by 38 · see citing works

Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1Η MRS) in children with Down syndrome

Śmigielska–Kuzia, J., Boćkowski, L., Sobaniec, W., Kułąk, W., & Sendrowski, K. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70369-8 · Cited by 37 · see citing works

Facilitation of avoidance learning by pentylenetetrazol as a function of task difficulty, deprivation and shock level

Krivanek, J. A. (1971) · Psychopharmacology · doi:10.1007/bf00402098 · Cited by 35 · see citing works

Enhancement of performance by methyl β-carboline-3-carboxylate, in learning and memory tasks

Venault, P., Chapouthier, G., Simiand, J., Dodd, R. H., & Rossier, J. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90105-5 · Cited by 32 · see citing works

Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model

Möhler, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.028 · Cited by 30 · see citing works

Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome.

Smigielska-Kuzia, J., & Sobaniec, W. (2007) · PubMed · Cited by 30 · see citing works

Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model for Down syndrome

Martínez‐Cué, C., Rueda, N., García, E., & Flórez, J. (2005) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2005.00175.x · Cited by 29 · see citing works

Developmentally Altered Inhibition in Ts65Dn, a mouse model of Down syndrome

Mitra, A., Blank, M., & Madison, D. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.034 · Cited by 28 · see citing works

Randomized clinical investigation of Ro 15-1788, a benzodiazepine antagonist, in reversing the central effects of flunitrazepam.

Jensen, S., KIRKEGAARD, L., & Bn, A. (1987) · PubMed · Cited by 26 · see citing works

Occupancy of human brain GABAA receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [11C]flumazenil PET imaging

Eng, W., Atack, J. R., Bergström, M., Sanabria, S., Appel, L., Dawson, G. R., Sciberras, D. G., Hargreaves, R. J., Långström, B., & Burns, H. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.024 · Cited by 20 · see citing works

Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down’s syndrome

Szemes, M., Davies, R. L., Garden, C. L. P., & Usowicz, M. M. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-33 · Cited by 15 · see citing works

Isolation of pharmacologically distinct GABA-benzodiazepine receptors by protein chemistry and molecular cloning.

Rw, O., Bureau, M., Khrestchatisky, M., Aj, M., Chiang, M. Y., Tobin, A. J., Xu, W., Jackson, M., Sternini, C., & Brecha, N. C. (1990) · PubMed · Cited by 12 · see citing works

Characterization of the solubility of a poorly soluble hydroxylated metabolite in human urine and its implications for potential renal toxicity.

Merschman, S. A., Rose, M. J., Pearce, G. E. S., Woolf, E., Schaefer, B. H., Huber, A., Musson, D. G., Perry, K. J., Rush, D., Varsolona, R. J., et al. (2005) · PubMed · Cited by 10 · see citing works

Human Models Are Needed for Studying Human Neurodevelopmental Disorders

Zhao, X., & Bhattacharyya, A. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.009 · Cited by 192 · see citing works

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and Neuromorphological alterations found in a mouse model of down syndrome

García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104 · see citing works

Opportunities, barriers, and recommendations in Down syndrome research

Hendrix, J. A., Amon, A., Abbeduto, L., Agiovlasitis, S., Alsaied, T., Anderson, H. A., Bain, L. J., Baumer, N., Bhattacharyya, A., Bogunovic, D., et al. (2021) · Translational Science of Rare Diseases · doi:10.3233/trd-200090 · Cited by 100 · see citing works

Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?

Dekker, A. D., Strydom, A., Coppus, A. M. W., Nižetić, D., Vermeiren, Y., Naudé, P. J. W., Dam, D. V., Potier, M., Fortea, J., & Deyn, P. P. D. (2015) · Cortex · doi:10.1016/j.cortex.2015.07.032 · Cited by 96 · see citing works

Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future

Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01728-8 · Cited by 94 · see citing works

GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy

Johansson, M., Agustí, A., Llansola, M., Montoliu, C., Strömberg, J., Malinina, E., Ragagnin, G., Doverskog, M., Bäckström, T. C., & Felipo, V. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00073.2015 · Cited by 76 · see citing works

GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome

Martín, J. Z. D. S., Delabar, J. M., Bacci, A., & Potier, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.002 · Cited by 64 · see citing works

Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders

Lam, P., Newland, J., Faull, R. L. M., & Kwakowsky, A. (2023) · Molecules · doi:10.3390/molecules28031344 · Cited by 60 · see citing works

Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome

Lysenko, L. V., Kim, J., Henry, C. L., Tyrtyshnaia, A. A., Kohnz, R. A., Madamba, F., Simon, G. M., Kleschevnikova, N. E., Nomura, D. K., Ezekowitz, R. A. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114521 · Cited by 57 · see citing works

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome

Kleschevnikov, A. M., Yu, J., Kim, J., Lysenko, L. V., Zeng, Z., Yu, Y. E., & Mobley, W. C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.009 · Cited by 46 · see citing works

Disinhibition, an emerging pharmacology of learning and memory

Möhler, H., & Rudolph, U. (2017) · F1000Research · doi:10.12688/f1000research.9947.1 · Cited by 44 · see citing works

The Legacy of the Benzodiazepine Receptor

Möhler, H. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.10.008 · Cited by 43 · see citing works

Dissecting Alzheimer disease in Down syndrome using mouse models

Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 40 · see citing works

Γ-Aminobutyric acid in adult brain: an update

Siucińska, E. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112224 · Cited by 41 · see citing works

Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome

Schulz, J. M., Knoflach, F., Hernandez, M., & Bischofberger, J. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2723-18.2019 · Cited by 39 · see citing works

Altered patterning of trisomy 21 interneuron progenitors

Giffin-Rao, Y., Sheng, J., Strand, B., Xu, K., Huang, L., Medo, M., Risgaard, K. A., Dantinne, S., Mohan, S., Keshan, A., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.05.001 · Cited by 38 · see citing works

The α5-Containing GABAA Receptors—a Brief Summary

Mohamad, F. H., & Has, A. T. C. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1246-4 · Cited by 38 · see citing works

Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects

Zaki, M. E., El-Bassyouni, H. T., Tosson, A. M. S., Youness, E. R., & Hussein, J. (2016) · Jornal de Pediatria · doi:10.1016/j.jped.2016.04.012 · Cited by 38 · see citing works

Long‐lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5‐selective GABAA inverse agonist

Duchon, A., Gruart, A., Albac, C., Delatour, B., Martín, J. Z. D. S., Delgado-Garcia, J. M., Hérault, Y., & Potier, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14903 · Cited by 33 · see citing works

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Rueda, N., Flórez, J., Dierssen, M., & Martínez‐Cué, C. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.001 · Cited by 29 · see citing works

The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome

Milenković, I., Jarc, J., Dassler, E., Aronica, E., Iyer, A. M., Adle‐Biassette, H., Scharrer, A., Reischer, T., Hainfellner, J. A., & Kovács, G. G. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12406 · Cited by 29 · see citing works

Consequences of trisomy 21 for brain development in Down syndrome

Russo, M. L., Sousa, A. M. M., & Bhattacharyya, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00866-2 · Cited by 28 · see citing works

Dynamic Causal Modeling of the Relationship between Cognition and Theta–alpha Oscillations in Adults with Down Syndrome

Hamburg, S., Rosch, R. E., Startin, C. M., Friston, K. J., & Strydom, A. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz043 · Cited by 27 · see citing works

Brain circuit pathology in Down syndrome: from neurons to neural networks

Bartesaghi, R. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0067 · Cited by 25 · see citing works

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice

García-Cerro, S., Rueda, N., Vidal, V., Puente, A., Campa, V. M., Lantigua, S., Narcís, J. O., Velasco, A. L., Bartesaghi, R., & Martínez‐Cué, C. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa074 · Cited by 23 · see citing works

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

García-Cerro, S., Vidal, V., Lantigua, S., Berciano, M. T., Lafarga, M., Ramos‐Cabrer, P., Padró, D., Rueda, N., & Martínez‐Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.002 · Cited by 20 · see citing works

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18 · see citing works

Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome

Vidal, V., García-Cerro, S., Martinez, P. M., Corrales, A., Lantigua, S., Vidal, R., Rueda, N., Ozmen, L., Hernandez, M., & Martínez‐Cué, C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0675-3 · Cited by 17 · see citing works

Total Syntheses of Highly Oxidized Natural Products†

Wang, Y., & Qi, X. (2025) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202400898 · Cited by 16 · see citing works

Spaced training improves learning in Ts65Dn and Ube3a mouse models of intellectual disabilities

Lauterborn, J. C., Schultz, M. N., Le, A. A., Amani, M., Friedman, A. E., Leach, P. T., Gall, C. M., LYNCH, G. S., & Crawley, J. N. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0495-5 · Cited by 15 · see citing works

Negative modulation of α 5 GABA A receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion

Stamenić, T. T., Joksimovic, S. M., Biawat, P., Stanković, T., Marković, B. D., Cook, J. M., & Savić, M. M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115590601 · Cited by 12 · see citing works

GABAA receptor subunit deregulation in the hippocampus of human foetuses with Down syndrome

Milenkovic, I., Stojanovic, T., Aronica, E., Fülöp, L., Bozsó, Z., Máté, Z., Yanagawa, Y., Adle-Biassette, H., Lubec, G., Szabó, G., et al. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1563-3 · Cited by 15 · see citing works

Selective Modulation of α5 GABAA Receptors Exacerbates Aberrant Inhibition at Key Hippocampal Neuronal Circuits in APP Mouse Model of Alzheimer’s Disease

Petrache, A. L., Khan, A. A., Nicholson, M. W., Monaco, A., Kuta-Siejkowska, M., Haider, S. M., Hilton, S. T., Jovanovic, J. N., & Ali, A. B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.568194 · Cited by 12 · see citing works

Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?

Martínez‐Cué, C., & Bartesaghi, R. (2022) · Nutrients · doi:10.3390/nu14142880 · Cited by 11 · see citing works

Atypical electrophysiological and behavioral responses to diazepam in a leading mouse model of Down syndrome

Victorino, D. B., Pinheiro, D. J. L. L., Scott-McKean, J. J., Barker, S., Stasko, M. R., Faber, J., Scorza, C. A., & Costa, A. C. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-89011-y · Cited by 11 · see citing works

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

Nižetić, D., Chen, C., Hong, W., & Koo, E. H. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00299 · Cited by 9 · see citing works

Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment

Benke, D., & Möhler, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.030 · Cited by 10 · see citing works

GIRK2 Channels in Down Syndrome and Alzheimer’s Disease

Kleschevnikov, A. M. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221223122110 · Cited by 10 · see citing works

Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits

Kleschevnikov, A. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1006068 · Cited by 9 · see citing works

Meta-Analysis of Down Syndrome Cortical Development Reveals Underdeveloped State of the Science

Risgaard, K. A., Sorci, I. A., Mohan, S., & Bhattacharyya, A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.915272 · Cited by 7 · see citing works

Neuronal Networks Regulating Sleep and Arousal: Effect of Drugs

Szabadi, E. (2014) · Milestones in drug therapy · doi:10.1007/978-3-319-11514-6_2 · Cited by 8 · see citing works

Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects

Zaki, M. E., El-Bassyouni, H. T., Tosson, A. M. S., Youness, E. R., & Hussein, J. (2017) · Jornal de Pediatria (Versão em Português) · doi:10.1016/j.jpedp.2016.04.007 · Cited by 6 · see citing works

Altered synaptic functions in a humanized mouse model of down syndrome (TcMAC21): Implications for seizure susceptibility

Shao, L., & Stafstrom, C. E. (2025) · Epilepsy Research · doi:10.1016/j.eplepsyres.2025.107686 · Cited by 4 · see citing works

Neurodevelopmental Abnormalities in Down Syndrome: Assessing Structural and Functional Deficits

Robinson, J., Chawla, N., Patel, S., Spey, E., McNulty, O., & Kaur, G. (2024) · Cureus · doi:10.7759/cureus.76156 · Cited by 4 · see citing works

Early postnatal GABAB antagonist treatment normalizes inhibitory/excitatory balance in neonatal Ts65Dn mice, a genetic model of down syndrome

Jin, J., Doan, J., Fernandez, C., Nguyen, S., Spencer, C., & Kleschevnikov, A. M. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115171 · Cited by 3 · see citing works

Evolution of synthetic strategies and design for synthesis of (−)-picrotoxinin

Kha, T., & Doan, B. N. D. (2021) · Tetrahedron · doi:10.1016/j.tet.2021.132022 · Cited by 3 · see citing works

Modeling of human brain diseases in experiments on rodents (brief overview)

Perepelkina, O. V., Полетаева, И. И., & Tarasova, A. Y. (2016) · Journal of Modern Foreign Psychology · doi:10.17759/jmfp.2016050402 · Cited by 3 · see citing works

Drug Repurposing Patent Applications April–June 2015

Mucke, H. A. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.29030.pq2 · Cited by 3 · see citing works

A Dive Into Cerebellar Dysfunction, Motor Deficits and GABAergic Signaling in Down Syndrome

Feely, S., Rodriguez, M. R., Shannon, A., Young, S., Rosales, J. P., & Kaur, G. (2025) · Cureus · doi:10.7759/cureus.79623 · Cited by 2 · see citing works

Inhibitory system overstimulation plays a role in the pathogenesis of neuromuscular and neurological diseases: a novel hypothesis

Tuk, B. (2016) · F1000Research · doi:10.12688/f1000research.8774.1 · Cited by 2 · see citing works

Overstimulation of the inhibitory nervous system plays a role in the pathogenesis of neuromuscular and neurological diseases: a novel hypothesis

Tuk, B. (2016) · F1000Research · doi:10.12688/f1000research.8774.2 · Cited by 2 · see citing works

The impact of Mmu 17 non- Hsa 21 orthologous genes in the Ts65Dn mouse model of Down syndrome: the “gold standard” revisitedPreprint

Guedj, F., Kane, E., Bishop, L. A., Pennings, J. L. A., Hérault, Y., & Bianchi, D. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.23.509067 · Cited by 2 · see citing works

Chloride transporters in physiological brain development and neurodevelopmental disorders: The case of the Down syndrome

Savardi, A., Ziogas, I., Bolla, M., & Cancedda, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00021-2 · Cited by 1 · see citing works

The Neurochemical Mechanisms of the Pharmacological Activities of Inverse Agonists of the Benzodiazepine Binding Site

Головко, А. И., Ivanov, M. B., Головко, Е. С., Долго-Сабуров, В. Б., & Zatsepin, E. P. (2018) · Neurochemical Journal · doi:10.1134/s1819712418030042 · Cited by 1 · see citing works

Bicuculline restores frequency-dependent hippocampal I/E ratio and circuit function in PGC-1ɑ null mice

Bhattacharya, D., Bartley, A. F., Li, Q., & Dobrunz, L. E. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.07.003 · Cited by 1 · see citing works

Computational Approximations to Intellectual Disability in Down Syndrome

Tovar, Á. E., Moustafa, A. A., & Arias‐Trejo, N. (2017) · doi:10.1002/9781119159193.ch2

Les déficits cognitifs dans la trisomie 21, de la naissance à la démence : mécanismes et traitements

Potier, M. (2016) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30567-9

Differential Dose–Response Behavioural Profiles of Diazepam, Zolpidem and Indiplon in a Two-Trial Y-Maze Paradigm in Rats

Moraru, M. V., Coman, O. A., Zugravu, A., Stoleru, S., Ghiță, C. I. V., Costescu, M., Poenaru, E., Dragomir, A.-F., Barbu, A. C., Luncă, D.-C., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081282

Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome

Potier, M.-C., Braudeau, J., Dauphinot, L., & Delatour, B. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660185 · Cited by 34 · see citing works

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice

Braudeau, J., Delatour, B., Duchon, A., Pereira, P. L., Dauphinot, L., de Chaumont, F., Olivo‐Marín, J., Dodd, R. H., Hérault, Y., & Potier, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111405366 · Cited by 163 · see citing works

Estudio del efecto de la administración crónica de fármacos agonistas inversos selectivos para la subunidad a5 del receptor GABAa sobre los déficits cognitivos, electrofisiológicos y neuromorfológicos del ratón Ts65Dn, un modelo murino de síndrome de Down

Fernández, P. M. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome

Martínez‐Cué, C., Martinez, P. M., Rueda, N., Vidal, R., García-Cerro, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1203-12.2013 · Cited by 154 · see citing works

Long‐lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5‐selective GABAA inverse agonist

Duchon, A., Gruart, A., Albac, C., Delatour, B., Martín, J. Z. D. S., Delgado-Garcia, J. M., Hérault, Y., & Potier, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14903 · Cited by 33 · see citing works